基于先进的计算技术和实验验证实,确定新型TIGIT/PVR相互作用阻断剂的治疗潜力
Xudong Lü1, Xiyu Wei1, Chenyu Wang2
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Biophysical chemistry
|December 27, 2024
概括
研究人员发现了一种新型小分子,MCULE-5547257859,它有效地阻断了TIGIT/PVR相互作用. 这种化合物增强了免疫细胞的活动,为癌症治疗提供了一个有前途的新途径.
科学领域:
- 免疫学 免疫学 免疫学
- 计算化学的计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- TIGIT/PVR通路在免疫调节和癌症进展中起着至关重要的作用.
- 抑制TIGIT/PVR相互作用增强自然杀手 (NK) 和CD8+T细胞的细胞毒性活性,显示出抗癌潜力.
- 针对TIGIT的小分子抑制剂的开发仍然是一个挑战.
研究的目的:
- 确定能够抑制TIGIT/PVR相互作用的新型小分子.
- 评估已识别的化合物在癌症治疗中的治疗潜力.
主要方法:
- 利用结合XGBOOST机器学习和分子对接的计算选过程来识别潜在的TIGIT抑制剂.
- 通过体外阻断试验验验证了候选分子.
- 进行了分子动力学模拟和结合自由能分析,以评估结合亲和力和稳定性.
主要成果:
- 一种计算方法有效地减少了用于抑制剂选的化学空间.
- 化合物MCULE-5547257859在阻断试验中证明了TIGIT/PVR相互作用的最强烈抑制.
- 分子动力学模拟证实了MCULE-5547257859对TIGIT的热力学稳定构造和强大的结合亲和力.
结论:
- 化合物MCULE-5547257859有效地抑制了TIGIT/PVR相互作用.
- 这种化合物代表了瘤学应用的有前途的新型治疗候选物.
- 这项研究强调了计算方法在加速癌症免疫治疗药物发现方面的潜力.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140